Insulin Mutation Screening in 1,044 Patients With Diabetes

TABLE 2

Clinical characteristics of probands diagnosed in infancy and their family members with an INS gene mutation

Age at diagnosis (weeks and years) All subjects
0–26 weeks 27–52 weeks 1–45 years
n 39 5 2 46
Sex (% male) 19 of 39 (49) 2of 5 (40%) 2 (100%) 23 of 46 (50%)
Current age (years) 10 (0.5–42) 16 (1–45) 42 (35–48) 14 (0.5–48)
Current BMI (kg/m2) 17 (11–36) 18 (16–30) NA 17 (11–36)
Birth weight (kg) 2.6 (1.7–3.8) 3 (2.9–3.9) 2.7 (2.4–2.9) 2.7 (1.7–3.9)
Gestational age (weeks) 40 (35–42) 40 (37–42) 40 40 (35–42)
Corrected birth weight (centile) 3 (<1st–87th) 44 (5th–83rd) 4.5 (<1st–8th) 6 (<1st–87th)
Age at diagnosis (weeks and years) 9 weeks (0–26) 35 weeks (31–48) 14.5 years (7–22) 11 weeks (0–1,144)
Insulin treatment (%) 100 100 100 100
Insulin dose (units · kg−1 · day−1) 0.73 (0.3–1.9) 0.6 (0.2–0.7) 0.45 (0.3–0.6) 0.7 (0.3–1.9)
A1C 7.9 (4.6–13.8) 7.6 (6.5–9.5) NA 7.95 (4.6–13.8)
Antibody status: Neg./pos./NA 18/0/21 2/0/3 0/0/2 20/0/26
  • Data are median (range) unless otherwise indicated. NA, not available.

This Article

  1. Diabetes vol. 57 no. 4 1034-1042